JP2006516974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516974A5 JP2006516974A5 JP2006500750A JP2006500750A JP2006516974A5 JP 2006516974 A5 JP2006516974 A5 JP 2006516974A5 JP 2006500750 A JP2006500750 A JP 2006500750A JP 2006500750 A JP2006500750 A JP 2006500750A JP 2006516974 A5 JP2006516974 A5 JP 2006516974A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- formula
- carbonyl
- compound
- thieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- -1 1H-pyrrolo [2,3 -B] pyridin-3-ylmethyl Chemical group 0.000 claims description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 229910052717 sulfur Chemical group 0.000 claims description 8
- 239000011593 sulfur Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000001589 carboacyl group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000004982 dihaloalkyl group Chemical group 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 5
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 5
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 4
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims description 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- JGOOQALRLGHKIY-UHFFFAOYSA-N 1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)NC2=C1C=CS2 JGOOQALRLGHKIY-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
- VQBYQQAWHSCZET-UHFFFAOYSA-N 1,3-oxazolidin-2-ol Chemical compound OC1NCCO1 VQBYQQAWHSCZET-UHFFFAOYSA-N 0.000 claims 1
- NMHRECIQUFFUHV-NRFANRHFSA-N 1-cyclopropyl-6-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC1=NNC(C)=C1CC1=C(C(=O)N2OC[C@@](C)(O)C2)C(C(=O)N(C)C(=O)N2C3CC3)=C2S1 NMHRECIQUFFUHV-NRFANRHFSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- PRNXOFBDXNTIFG-HXUWFJFHSA-N 5-[(4r)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-6-[[5-methyl-3-(trifluoromethyl)-1h-pyrazol-4-yl]methyl]-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(C(C)C)C=2SC=1CC1=C(C)NN=C1C(F)(F)F PRNXOFBDXNTIFG-HXUWFJFHSA-N 0.000 claims 1
- YVFBMNCDAFQCEQ-QHCPKHFHSA-N 5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propan-2-yl-6-(1h-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C(C)C)C=2SC(CC=2C3=CC=CN=C3NC=2)=C1C(=O)N1C[C@](C)(O)CO1 YVFBMNCDAFQCEQ-QHCPKHFHSA-N 0.000 claims 1
- RYCSBKCBICNZBS-MHZLTWQESA-N 5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propan-2-yl-6-[(4-pyridin-2-ylphenyl)methyl]thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(C(C)C)C=2SC=1CC(C=C1)=CC=C1C1=CC=CC=N1 RYCSBKCBICNZBS-MHZLTWQESA-N 0.000 claims 1
- SPMGLYKATLKNRK-SANMLTNESA-N 5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propan-2-yl-6-[(4-pyrimidin-2-ylphenyl)methyl]thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(C(C)C)C=2SC=1CC(C=C1)=CC=C1C1=NC=CC=N1 SPMGLYKATLKNRK-SANMLTNESA-N 0.000 claims 1
- VNXZYGDWCBUEDR-VWLOTQADSA-N 5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propyl-6-(quinolin-4-ylmethyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C1=2C(=O)N(C)C(=O)N(CCC)C=2SC(CC=2C3=CC=CC=C3N=CC=2)=C1C(=O)N1C[C@](C)(O)CO1 VNXZYGDWCBUEDR-VWLOTQADSA-N 0.000 claims 1
- YIOZKLDAZRCZTF-VWLOTQADSA-N 5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-6-[(1-phenylpyrazol-4-yl)methyl]-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(C(C)C)C=2SC=1CC(=C1)C=NN1C1=CC=CC=C1 YIOZKLDAZRCZTF-VWLOTQADSA-N 0.000 claims 1
- SOFSLARRWWWVMX-DEOSSOPVSA-N 5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-6-[[5-methyl-1-pyrimidin-2-yl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(C(C)C)C=2SC=1CC(C(=N1)C(F)(F)F)=C(C)N1C1=NC=CC=N1 SOFSLARRWWWVMX-DEOSSOPVSA-N 0.000 claims 1
- PRNXOFBDXNTIFG-FQEVSTJZSA-N 5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-6-[[5-methyl-3-(trifluoromethyl)-1h-pyrazol-4-yl]methyl]-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(C(C)C)C=2SC=1CC1=C(C)NN=C1C(F)(F)F PRNXOFBDXNTIFG-FQEVSTJZSA-N 0.000 claims 1
- RHPDPKAYECJJOK-QFIPXVFZSA-N 6-(benzotriazol-1-ylmethyl)-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C(C)C)C=2SC(CN2C3=CC=CC=C3N=N2)=C1C(=O)N1C[C@](C)(O)CO1 RHPDPKAYECJJOK-QFIPXVFZSA-N 0.000 claims 1
- ORBWWPHPDXXVIW-FQEVSTJZSA-N 6-[(2,4-dichloro-1,3-thiazol-5-yl)methyl]-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-(2-methylpropyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(CC(C)C)C=2SC=1CC=1SC(Cl)=NC=1Cl ORBWWPHPDXXVIW-FQEVSTJZSA-N 0.000 claims 1
- UDSVFQFDRPEYFT-SANMLTNESA-N 6-[(3,5-dimethyl-1-pyridin-4-ylpyrazol-4-yl)methyl]-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(C(C)C)C=2SC=1CC(=C1C)C(C)=NN1C1=CC=NC=C1 UDSVFQFDRPEYFT-SANMLTNESA-N 0.000 claims 1
- SSTJOCQSNJYCFD-SANMLTNESA-N 6-[(3,5-dimethyl-1-pyrimidin-2-ylpyrazol-4-yl)methyl]-5-[(4s)-4-ethyl-4-hydroxy-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C1[C@](CC)(O)CON1C(=O)C(C=1C(=O)N(C)C(=O)N(C(C)C)C=1S1)=C1CC1=C(C)N(C=2N=CC=CN=2)N=C1C SSTJOCQSNJYCFD-SANMLTNESA-N 0.000 claims 1
- LWYGNDILOYWFHU-VWLOTQADSA-N 6-[(3,5-dimethyl-1-pyrimidin-2-ylpyrazol-4-yl)methyl]-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(C(C)C)C=2SC=1CC(=C1C)C(C)=NN1C1=NC=CC=N1 LWYGNDILOYWFHU-VWLOTQADSA-N 0.000 claims 1
- FKIUQMBRQLGLAC-QFIPXVFZSA-N 6-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-(2-methylpropyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(CC(C)C)C=2SC=1CC=1C(C)=NNC=1C FKIUQMBRQLGLAC-QFIPXVFZSA-N 0.000 claims 1
- KWSDOBIBNMXOEI-NRFANRHFSA-N 6-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(CCC)C=2SC=1CC=1C(C)=NNC=1C KWSDOBIBNMXOEI-NRFANRHFSA-N 0.000 claims 1
- JLYZHDWGRCXGHD-NRFANRHFSA-N 6-[(3-bromothiophen-2-yl)methyl]-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-(2-methylpropyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(CC(C)C)C=2SC=1CC=1SC=CC=1Br JLYZHDWGRCXGHD-NRFANRHFSA-N 0.000 claims 1
- CPRZLKUKNIGNHC-IBGZPJMESA-N 6-[(4,5-dichloro-2-methylimidazol-1-yl)methyl]-1-ethyl-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C([C@@](C)(O)C1)ON1C(=O)C=1C=2C(=O)N(C)C(=O)N(CC)C=2SC=1CN1C(C)=NC(Cl)=C1Cl CPRZLKUKNIGNHC-IBGZPJMESA-N 0.000 claims 1
- IXYCVRJQEKQPFU-VWLOTQADSA-N 6-[(8-fluoroquinolin-4-yl)methyl]-5-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C(C)C)C=2SC(CC=2C3=CC=CC(F)=C3N=CC=2)=C1C(=O)N1C[C@](C)(O)CO1 IXYCVRJQEKQPFU-VWLOTQADSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical group ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300119A SE0300119D0 (sv) | 2003-01-17 | 2003-01-17 | Novel compounds |
| PCT/SE2004/000052 WO2004065394A1 (en) | 2003-01-17 | 2004-01-15 | Thienopyrimidinediones and their use in the modulation of autoimmune disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006516974A JP2006516974A (ja) | 2006-07-13 |
| JP2006516974A5 true JP2006516974A5 (https=) | 2010-01-21 |
| JP4519121B2 JP4519121B2 (ja) | 2010-08-04 |
Family
ID=20290154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500750A Expired - Fee Related JP4519121B2 (ja) | 2003-01-17 | 2004-01-15 | 自己免疫疾患の調節におけるチエノピリミジンジオンとその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7384951B2 (https=) |
| EP (1) | EP1587812B1 (https=) |
| JP (1) | JP4519121B2 (https=) |
| KR (2) | KR20110125256A (https=) |
| CN (1) | CN100334093C (https=) |
| AT (1) | ATE335748T1 (https=) |
| AU (1) | AU2004206012B2 (https=) |
| BR (1) | BRPI0406801B8 (https=) |
| CA (1) | CA2512441C (https=) |
| DE (1) | DE602004001857T2 (https=) |
| EG (1) | EG25613A (https=) |
| ES (1) | ES2270337T3 (https=) |
| IL (1) | IL169370A (https=) |
| IS (1) | IS2376B (https=) |
| MX (1) | MXPA05007496A (https=) |
| NO (1) | NO333702B1 (https=) |
| NZ (1) | NZ541217A (https=) |
| PL (1) | PL214682B1 (https=) |
| RU (1) | RU2331647C2 (https=) |
| SE (1) | SE0300119D0 (https=) |
| UA (1) | UA81788C2 (https=) |
| WO (1) | WO2004065394A1 (https=) |
| ZA (1) | ZA200505364B (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117583D0 (en) | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
| GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| RU2332420C2 (ru) * | 2003-01-17 | 2008-08-27 | Астразенека Аб | Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания |
| SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| AU2006272951A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| CN102206216B (zh) | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| AU2007336811A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| GB0713479D0 (en) * | 2007-07-11 | 2007-08-22 | Syngenta Participations Ag | Substituted aromatic heterocyclic compounds as fungicides |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| WO2010089580A1 (en) | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
| PT2411395E (pt) * | 2009-03-23 | 2013-06-06 | Glenmark Pharmaceuticals Sa | Derivados de furopirimidinadiona como moduladores de trpa1 |
| DK2411397T3 (da) * | 2009-03-23 | 2013-08-05 | Glenmark Pharmaceuticals Sa | Isothiazol-pyrimidindionderivater som modulatorer af TRPA1 |
| KR101739994B1 (ko) | 2009-04-03 | 2017-05-25 | 에프. 호프만-라 로슈 아게 | 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도 |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| KR101911972B1 (ko) | 2011-02-07 | 2018-10-25 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| EP2804852A2 (en) | 2012-01-20 | 2014-11-26 | Regents Of The University Of Minnesota | Therapeutic compounds |
| GB2523211B (en) | 2012-01-27 | 2020-03-18 | Univ Jefferson | MCT protein inhibitor-related prognostic and therapeutic methods |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| WO2014172627A1 (en) | 2013-04-19 | 2014-10-23 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
| MY184561A (en) * | 2013-10-21 | 2021-04-03 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
| CA2974697A1 (en) | 2015-01-22 | 2016-07-28 | The Scripps Research Institute | Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters |
| UY36586A (es) * | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
| KR101730536B1 (ko) * | 2016-03-17 | 2017-05-02 | 주식회사 골프존 | 스크린 골프 시스템에서 구현되는 컨텐츠 전송 서비스 방법, 컨텐츠 전송 서비스를 위한 모바일 단말기의 제어방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록매체 |
| KR101712836B1 (ko) * | 2016-03-17 | 2017-03-22 | 주식회사 골프존 | 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체 |
| KR101712838B1 (ko) * | 2016-03-17 | 2017-03-07 | 주식회사 골프존 | 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체 |
| TWI823932B (zh) * | 2018-05-11 | 2023-12-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 三唑并嘧啶化合物及其在治療癌症中之用途 |
| CN119080799B (zh) * | 2024-09-27 | 2025-12-05 | 山东大学 | 一种n-羟基噻吩并嘧啶二酮类衍生物及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US738495A (en) * | 1902-12-26 | 1903-09-08 | William E Sherwood | Thill-coupling. |
| US6469014B1 (en) * | 1997-05-28 | 2002-10-22 | Astrazeneca Ab | Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy |
| SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| IL136499A0 (en) | 1997-12-05 | 2001-06-14 | Astrazeneca Uk Ltd Astrazeneca | Pyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pypyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pyridazinone compounds, process for their preparatioridaziones compounds, process for their preparation, pharmaceutical compositions containing them, a n, pharmaceutical compositions containing them, a process for prepating the pharmaceutical compositiprocess for preparing the pharmaceutical compositions, and use thereof ons, and use thereof |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| ATE253580T1 (de) * | 1998-08-28 | 2003-11-15 | Astrazeneca Ab | Neue thieno(2,3-d)pyrimidindione, verfahren für ihre herstellung und ihre verwendung in der therapie |
| ATE272642T1 (de) * | 2000-05-04 | 2004-08-15 | Astrazeneca Ab | Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel |
| GB0117583D0 (en) | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
| GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| RU2332420C2 (ru) | 2003-01-17 | 2008-08-27 | Астразенека Аб | Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания |
-
2003
- 2003-01-17 SE SE0300119A patent/SE0300119D0/xx unknown
-
2004
- 2004-01-15 KR KR1020117022785A patent/KR20110125256A/ko not_active Withdrawn
- 2004-01-15 WO PCT/SE2004/000052 patent/WO2004065394A1/en not_active Ceased
- 2004-01-15 DE DE602004001857T patent/DE602004001857T2/de not_active Expired - Lifetime
- 2004-01-15 RU RU2005121494/04A patent/RU2331647C2/ru not_active IP Right Cessation
- 2004-01-15 AT AT04702477T patent/ATE335748T1/de not_active IP Right Cessation
- 2004-01-15 US US10/542,197 patent/US7384951B2/en not_active Expired - Lifetime
- 2004-01-15 CA CA2512441A patent/CA2512441C/en not_active Expired - Lifetime
- 2004-01-15 BR BRPI0406801A patent/BRPI0406801B8/pt not_active IP Right Cessation
- 2004-01-15 CN CNB2004800071073A patent/CN100334093C/zh not_active Expired - Fee Related
- 2004-01-15 NZ NZ541217A patent/NZ541217A/en not_active IP Right Cessation
- 2004-01-15 PL PL378222A patent/PL214682B1/pl unknown
- 2004-01-15 EP EP04702477A patent/EP1587812B1/en not_active Expired - Lifetime
- 2004-01-15 JP JP2006500750A patent/JP4519121B2/ja not_active Expired - Fee Related
- 2004-01-15 UA UAA200506377A patent/UA81788C2/uk unknown
- 2004-01-15 MX MXPA05007496A patent/MXPA05007496A/es active IP Right Grant
- 2004-01-15 ES ES04702477T patent/ES2270337T3/es not_active Expired - Lifetime
- 2004-01-15 KR KR1020057013126A patent/KR101107486B1/ko not_active Expired - Fee Related
- 2004-01-15 AU AU2004206012A patent/AU2004206012B2/en not_active Ceased
-
2005
- 2005-06-23 IL IL169370A patent/IL169370A/en active IP Right Grant
- 2005-07-01 ZA ZA2005/05364A patent/ZA200505364B/en unknown
- 2005-07-12 EG EGNA2005000380 patent/EG25613A/xx active
- 2005-07-29 IS IS7965A patent/IS2376B/is unknown
- 2005-08-15 NO NO20053826A patent/NO333702B1/no not_active IP Right Cessation
-
2008
- 2008-05-05 US US12/115,171 patent/US20080214579A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516974A5 (https=) | ||
| RU2331647C2 (ru) | Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания | |
| JP2004538316A5 (https=) | ||
| RU2004102392A (ru) | Тиенопиримидиндионы и их использование в модулировании аутоиммунных заболеваний | |
| US10351532B2 (en) | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | |
| AU2002355732B2 (en) | Benzimidazo[4,5-f]isoquinolinone derivatives | |
| JP6373978B2 (ja) | イミダゾピロリジノン誘導体および疾患の処置におけるその使用 | |
| JP6181862B2 (ja) | ピラゾロピロリジン誘導体および疾患の処置におけるその使用 | |
| EP2552907B1 (en) | Pyridyltriazoles | |
| HRP20120174T1 (hr) | Derivat policikličnog cinamida | |
| SG187548A1 (en) | New aminopyrazoloquinazolines | |
| KR101666293B1 (ko) | Pde10 억제제로서 트라이아졸로 화합물 | |
| JP2004537557A5 (https=) | ||
| JP2009528389A5 (https=) | ||
| MX2008001035A (es) | Derivados de pirazina utiles como antagonistas del receptor de adenosina. | |
| KR920019794A (ko) | 융합 헤테로시클릭 화합물, 그의 제조방법 및 용도 | |
| RU2012117394A (ru) | Бензоксепиновые ингибиторы pi3 и способы применения | |
| WO2008072778A1 (ja) | 尿路系疾患の処置剤 | |
| US20150133425A1 (en) | Thienopyrimidines | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| HRP20160649T1 (hr) | Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba | |
| JP2023551290A (ja) | ピロリジン誘導体及び使用方法 | |
| US20240109900A1 (en) | Azabicyclic shp2 inhibitors | |
| CA2833192C (en) | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors | |
| JP2020533345A5 (https=) |